Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | MME | P08473 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 1/20 | 0.36 |
| ▸ | CPA1 | P15085 | 1/20 | 0.36 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.36 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.35 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20529784 | 1.00 | ALDH1A1 (0.46) | ALDH1A1MAPTMMEACECPA1 | |
| SCHEMBL20529783 | 1.00 | ALDH1A1 (0.46) | ALDH1A1MAPTMMEACECPA1 | |
| SCHEMBL20529782 | 1.00 | ALDH1A1 (0.46) | ALDH1A1MAPTMMEACECPA1 | |
| SCHEMBL29425334 | 0.83 | FAAH (0.41) | ALDH1A1MAPTMMEACECPA1 | |
| SCHEMBL15542780 | 0.83 | FAAH (0.41) | ALDH1A1MAPTMMEACECPA1 | |
| SCHEMBL21248496 | 0.83 | FAAH (0.41) | ALDH1A1MAPTMMEACECPA1 | |
| SCHEMBL16095430 | 0.83 | FAAH (0.41) | ALDH1A1MAPTMMEACECPA1 | |
| SCHEMBL17079552 | 0.83 | FAAH (0.41) | ALDH1A1MAPTMMEACECPA1 | |
| SCHEMBL15201831 | 0.83 | FAAH (0.41) | ALDH1A1MAPTMMEACECPA1 | |
| SCHEMBL20529774 | 0.80 | FAAH (0.49) | MAPTFAAHSMN1; SMN2SLC6A5CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210324029-A1 | STABLE MODULATORS OF GAMMA-C-CYTOKINE ACTIVITY | Bioniz Therapeutics, Inc. | 2021-10-21 | — | — | US | claimed |
| EP-3606940-A1 | STABLE MODULATORS OF GAMMA-C-CYTOKINE ACTIVITY | Bioniz, LLC (US) | 2020-02-12 | — | — | EP | claimed |
| WO-2018187499-A1 | STABLE MODULATORS OF GAMMA-C-CYTOKINE ACTIVITY | BIONIZ, LLC (US) | 2018-10-11 | — | — | WO | claimed |
| US-12600757-B2 | Peptides inhibiting gamma-c-cytokine activity and methods of use | Bioniz Therapeutics, Inc. (US) | 2026-04-14 | — | — | US | disclosed |
| US-20210324029-A1 | STABLE MODULATORS OF GAMMA-C-CYTOKINE ACTIVITY | Bioniz Therapeutics, Inc. | 2021-10-21 | — | — | US | disclosed |
| EP-3606940-A1 | STABLE MODULATORS OF GAMMA-C-CYTOKINE ACTIVITY | Bioniz, LLC (US) | 2020-02-12 | — | — | EP | disclosed |
| WO-2018187499-A1 | STABLE MODULATORS OF GAMMA-C-CYTOKINE ACTIVITY | BIONIZ, LLC (US) | 2018-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12600757-B2 | Peptides inhibiting gamma-c-cytokine activity and methods of use | IL15, IL2, IL15RA | ALDH1A1 3007/4885MAPT 667/4885MME 2936/4885 |
| US-20210324029-A1 | STABLE MODULATORS OF GAMMA-C-CYTOKINE ACTIVITY | IL2, IL2RA, GMFG | ALDH1A1 3771/4885MAPT 2789/4885MME 3222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.